Real-world Use of Ticagrelor versus Clopidogrel in PCI-treated STEMI Patients: A Single-Center Registry Study

ConclusionTicagrelor was preferred in low bleeding risk patients, which may have contributed to less BARC3-5 bleeding and lower mortality for T-DAPT. Thus bleeding mitigation is a clinical priority when selecting DAPT for PCI-treated STEMI patients. Continuation of initial DAPT regimen was typical, but early switching from clopidogrel to ticagrelor shows willingness to optimise DAPT. Patients with very low CRUSADE scores (<21.5) may be appropriate for switching to a potent P2Y12 inhibitor.
Source: Journal of the Saudi Heart Association - Category: Cardiology Source Type: research